Etentamig (ABBV-383)
A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of Etentamig Monotherapy or Etentamig Combinations in Subjects With Multiple Myeloma
Arms / Cohorts
Experimental:Substudy 1: Etentamig Dose Escalation
Accepting patients
Experimental:Substudy 4: Etentamig Dose Expansion
Accepting patients
Active Comparator:Substudy 3: Comparator
Accepting patients
Experimental:Substudy 4: Etentamig Dose Expansion
Accepting patients
Active Comparator:Substudy 1: Comparator
Accepting patients
Experimental:Substudy 1: Etentamig Dose Expansion
Accepting patients
Active Comparator:Substudy 2: Comparator
Accepting patients
Experimental:Substudy 2: Etentamig Dose Expansion
Accepting patients
Experimental:Substudy 3: Etentamig Dose Expansion
Accepting patients
Experimental:Substudy 3: Etentamig Dose Escalation
Accepting patients
Experimental:Substudy 4: Etentamig Dose Escalation
Accepting patients
Experimental:Substudy 3: Etentamig Dose Expansion
Accepting patients
Experimental:Substudy 2: Etentamig Dose Escalation
Accepting patients
Experimental:Substudy 1: Etentamig Dose Expansion
Accepting patients
Experimental:Substudy 2: Etentamig Dose Expansion
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.